A novel Iowa–Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction
Kalyan Nadiminti(University of Iowa Hospitals and Clinics), Sarah L. Mott(University of Iowa), Yogesh Jethava(University of Iowa), Bradley T. Loeffler(University of Iowa), Hassan B. Alkhateeb(Mayo Clinic), Ehsan Shabbir(Wright State University), Mehrdad Hefazi(Mayo Clinic), Mrinal M. Patnaik(Mayo Clinic), William J. Hogan(Mayo Clinic), Mark R. Litzow(Mayo Clinic in Arizona), Kimberly J. Langer(Mayo Clinic), Umar Farooq(Wake Forest University), Lindsay Dozeman(University of Iowa Hospitals and Clinics), Margarida Silverman(University of Iowa Hospitals and Clinics), Mithun Vinod Shah(Mayo Clinic in Arizona)
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k